Physician profile
Cheri E Tedford
NPI 1639436082
$1,925.02
in general payments reported to CMS, 2019-2025
18 companies · $249 in 2025
The $249 reported for 2025 was more than what 80% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $434 · 2023: $498 · 2024: $250 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $423.07 | 2021-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $303.52 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $243.52 | 2021-2025 | Dyanavel Xr |
| Kaleo, INC. | $176.09 | 2021-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $130.40 | 2021-2024 | Ninlaro |
| Sanofi Pasteur INC. | $126.09 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $109.40 | 2021-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Pfizer INC. | $80.91 | 2022-2025 | |
| Neurelis, INC. | $75.00 | 2022-2025 | Valtoco |
| Seqirus USA INC | $49.13 | 2023 | Flucelvax Quadrivalent |
| Sobi, INC | $47.69 | 2023 | |
| Supernus Pharmaceuticals, INC. | $39.89 | 2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $30.76 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $28.84 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.83 | 2023 | Flumist Quadrivalent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $15.49 | 2024 | Cotempla Xr-Odt |
| Ultragenyx Pharmaceutical INC. | $15.31 | 2021 | |
| Kyowa Kirin, INC. | $13.08 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheri Tedford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.